|
2020-09-22 |
2020-09-18 |
PS
Planned sale
|
Hardiman Roy C.
Chief Business Officer
Officer
|
5,000
-4.1%
99.98
USD 499,918
|
5,000
-4.1%
|
99.98
|
USD 499,918
|
|
|
2020-08-20 |
2020-08-18 |
PS
Planned sale
|
CHAI CHRISTOPHER Y
Chief Financial Officer
Officer
|
7,500
-67.9%
99.37
USD 745,240
|
7,500
-67.9%
|
99.37
|
USD 745,240
|
|
|
2020-08-20 |
2020-08-18 |
PS
Planned sale
|
Thomas Dolca
Chief Medical Officer
Officer
|
15,000
-89.1%
100.00
USD 1,500,000
|
15,000
-89.1%
|
100.00
|
USD 1,500,000
|
|
|
2020-08-12 |
2020-08-10 |
PS
Planned sale
|
Goldstein David M
Chief Scientific Officer
Officer
|
100
-0.3%
93.34
USD 9,334
|
100
-0.3%
|
93.34
|
USD 9,334
|
|
|
2020-08-12 |
2020-08-10 |
PS
Planned sale
|
Goldstein David M
Chief Scientific Officer
Officer
|
1,108
-3.4%
90.99
USD 100,816
|
1,108
-3.4%
|
90.99
|
USD 100,816
|
|
|
2020-08-12 |
2020-08-10 |
PS
Planned sale
|
Goldstein David M
Chief Scientific Officer
Officer
|
700
-2.1%
89.68
USD 62,773
|
700
-2.1%
|
89.68
|
USD 62,773
|
|
|
2020-08-12 |
2020-08-10 |
PS
Planned sale
|
Goldstein David M
Chief Scientific Officer
Officer
|
2,534
-7.0%
88.40
USD 224,012
|
2,534
-7.0%
|
88.40
|
USD 224,012
|
|
|
2020-08-12 |
2020-08-10 |
PS
Planned sale
|
Goldstein David M
Chief Scientific Officer
Officer
|
700
-1.9%
86.92
USD 60,844
|
700
-1.9%
|
86.92
|
USD 60,844
|
|
|
2020-08-12 |
2020-08-10 |
PS
Planned sale
|
Goldstein David M
Chief Scientific Officer
Officer
|
858
-2.3%
86.11
USD 73,886
|
858
-2.3%
|
86.11
|
USD 73,886
|
|
|
2020-07-17 |
2020-07-15 |
PS
Planned sale
|
Thomas Dolca
Chief Medical Officer
Officer
|
15,000
-89.1%
80.07
USD 1,201,070
|
15,000
-89.1%
|
80.07
|
USD 1,201,070
|
|
|
2020-07-02 |
2020-07-01 |
PS
Planned sale
|
Colowick Alan
Non-Executive Director
|
7,500
-100.0%
60.00
USD 450,000
|
7,500
-100.0%
|
60.00
|
USD 450,000
|
|
|
2020-06-25 |
2020-06-23 |
PS
Planned sale
|
Babler Martin
President, CEO
Executive Director
|
2,502
-75.5%
62.38
USD 156,078
|
2,502
-75.5%
|
62.38
|
USD 156,078
|
|
|
2020-06-25 |
2020-06-23 |
PS
Planned sale
|
Babler Martin
President, CEO
Executive Director
|
11,983
-78.3%
61.82
USD 740,745
|
11,983
-78.3%
|
61.82
|
USD 740,745
|
|
|
2020-06-25 |
2020-06-23 |
PS
Planned sale
|
Babler Martin
President, CEO
Executive Director
|
515
-3.3%
60.32
USD 31,066
|
515
-3.3%
|
60.32
|
USD 31,066
|
|
|
2020-06-17 |
2020-06-15 |
PS
Planned sale
|
Wolff Stefani
Chief Development Officer
Officer
|
100
-0.5%
61.37
USD 6,137
|
100
-0.5%
|
61.37
|
USD 6,137
|
|
|
2020-06-17 |
2020-06-15 |
PS
Planned sale
|
Wolff Stefani
Chief Development Officer
Officer
|
5,004
-20.7%
60.81
USD 304,291
|
5,004
-20.7%
|
60.81
|
USD 304,291
|
|
|
2020-06-17 |
2020-06-15 |
PS
Planned sale
|
Wolff Stefani
Chief Development Officer
Officer
|
400
-1.6%
59.89
USD 23,957
|
400
-1.6%
|
59.89
|
USD 23,957
|
|
|
2020-06-15 |
2020-06-12 |
PS
Planned sale
|
Hardiman Roy C.
Chief Business Officer
Officer
|
863
-0.7%
62.13
USD 53,617
|
863
-0.7%
|
62.13
|
USD 53,617
|
|
|
2020-06-15 |
2020-06-12 |
PS
Planned sale
|
Hardiman Roy C.
Chief Business Officer
Officer
|
2,542
-2.1%
61.62
USD 156,630
|
2,542
-2.1%
|
61.62
|
USD 156,630
|
|
|
2020-06-15 |
2020-06-12 |
PS
Planned sale
|
Hardiman Roy C.
Chief Business Officer
Officer
|
1,595
-1.3%
59.90
USD 95,541
|
1,595
-1.3%
|
59.90
|
USD 95,541
|
|
|
2020-05-21 |
2020-05-19 |
PS
Planned sale
|
CHAI CHRISTOPHER Y
Chief Financial Officer
Officer
|
7,500
-67.9%
65.10
USD 488,268
|
7,500
-67.9%
|
65.10
|
USD 488,268
|
|
|
2020-05-08 |
2020-05-07 |
PS
Planned sale
|
Goldstein David M
Chief Scientific Officer
Officer
|
2,719
-8.1%
60.39
USD 164,207
|
2,719
-8.1%
|
60.39
|
USD 164,207
|
|
|
2020-05-08 |
2020-05-07 |
PS
Planned sale
|
Goldstein David M
Chief Scientific Officer
Officer
|
3,281
-8.9%
59.96
USD 196,734
|
3,281
-8.9%
|
59.96
|
USD 196,734
|
|
|
2020-05-05 |
2020-05-05 |
PS
Planned sale
|
Colowick Alan
Non-Executive Director
|
6,660
-100.0%
60.00
USD 399,600
|
6,660
-100.0%
|
60.00
|
USD 399,600
|
|
|
2020-05-05 |
2020-05-01 |
PS
Planned sale
|
Colowick Alan
Non-Executive Director
|
840
-100.0%
60.07
USD 50,457
|
840
-100.0%
|
60.07
|
USD 50,457
|
|
|
2020-03-18 |
2020-03-16 |
PS
Planned sale
|
Wolff Stefani
Chief Development Officer
Officer
|
3,750
-9.5%
46.36
USD 173,838
|
3,750
-9.5%
|
46.36
|
USD 173,838
|
|
|
2020-03-18 |
2020-03-16 |
PS
Planned sale
|
Wolff Stefani
Chief Development Officer
Officer
|
1,754
-4.3%
45.72
USD 80,192
|
1,754
-4.3%
|
45.72
|
USD 80,192
|
|
|
2020-03-17 |
2020-03-13 |
PS
Planned sale
|
Hardiman Roy C.
Chief Business Officer
Officer
|
100
-0.1%
51.04
USD 5,104
|
100
-0.1%
|
51.04
|
USD 5,104
|
|
|
2020-03-17 |
2020-03-13 |
PS
Planned sale
|
Hardiman Roy C.
Chief Business Officer
Officer
|
1,181
-1.0%
49.46
USD 58,408
|
1,181
-1.0%
|
49.46
|
USD 58,408
|
|
|
2020-03-17 |
2020-03-13 |
PS
Planned sale
|
Hardiman Roy C.
Chief Business Officer
Officer
|
3,719
-3.1%
48.21
USD 179,304
|
3,719
-3.1%
|
48.21
|
USD 179,304
|
|
|
2020-03-05 |
2020-03-03 |
PS
Planned sale
|
Babler Martin
President, CEO
Executive Director
|
300
-0.8%
64.83
USD 19,448
|
300
-0.8%
|
64.83
|
USD 19,448
|
|
|
2020-03-05 |
2020-03-03 |
PS
Planned sale
|
Babler Martin
President, CEO
Executive Director
|
5,432
-12.1%
64.10
USD 348,180
|
5,432
-12.1%
|
64.10
|
USD 348,180
|
|
|
2020-03-05 |
2020-03-03 |
PS
Planned sale
|
Babler Martin
President, CEO
Executive Director
|
7,183
-13.8%
63.24
USD 454,251
|
7,183
-13.8%
|
63.24
|
USD 454,251
|
|
|
2020-03-05 |
2020-03-03 |
PS
Planned sale
|
Babler Martin
President, CEO
Executive Director
|
2,085
-3.8%
62.45
USD 130,203
|
2,085
-3.8%
|
62.45
|
USD 130,203
|
|
|
2020-02-20 |
2020-02-18 |
PS
Planned sale
|
CHAI CHRISTOPHER Y
Chief Financial Officer
Officer
|
76
-1.6%
68.52
USD 5,208
|
76
-1.6%
|
68.52
|
USD 5,208
|
|
|
2020-02-20 |
2020-02-18 |
PS
Planned sale
|
CHAI CHRISTOPHER Y
Chief Financial Officer
Officer
|
2,240
-31.6%
68.13
USD 152,612
|
2,240
-31.6%
|
68.13
|
USD 152,612
|
|
|
2020-02-20 |
2020-02-18 |
PS
Planned sale
|
CHAI CHRISTOPHER Y
Chief Financial Officer
Officer
|
605
-7.9%
67.08
USD 40,582
|
605
-7.9%
|
67.08
|
USD 40,582
|
|
|
2020-02-20 |
2020-02-18 |
PS
Planned sale
|
CHAI CHRISTOPHER Y
Chief Financial Officer
Officer
|
1,350
-14.9%
65.94
USD 89,021
|
1,350
-14.9%
|
65.94
|
USD 89,021
|
|
|
2020-02-20 |
2020-02-18 |
PS
Planned sale
|
CHAI CHRISTOPHER Y
Chief Financial Officer
Officer
|
545
-5.7%
64.91
USD 35,375
|
545
-5.7%
|
64.91
|
USD 35,375
|
|
|
2020-02-20 |
2020-02-18 |
PS
Planned sale
|
CHAI CHRISTOPHER Y
Chief Financial Officer
Officer
|
2,684
-21.9%
63.86
USD 171,389
|
2,684
-21.9%
|
63.86
|
USD 171,389
|
|
|
2020-02-12 |
2020-02-10 |
PS
Planned sale
|
Goldstein David
Chief Scientific Officer
Officer
|
5,200
-14.4%
71.11
USD 369,779
|
5,200
-14.4%
|
71.11
|
USD 369,779
|
|
|
2020-02-12 |
2020-02-10 |
PS
Planned sale
|
Goldstein David
Chief Scientific Officer
Officer
|
800
-2.2%
69.53
USD 55,622
|
800
-2.2%
|
69.53
|
USD 55,622
|
|
|
2019-12-20 |
2019-12-19 |
S
Sale
|
Thomas Dolca
Chief Medical Officer
Officer
|
495
-50.1%
60.00
USD 29,700
|
495
-50.1%
|
60.00
|
USD 29,700
|
|
|
2019-12-19 |
2019-12-18 |
PS
Planned sale
|
Babler Martin
President, CEO
Executive Director
|
1,295
-7.6%
54.28
USD 70,292
|
1,295
-7.6%
|
54.28
|
USD 70,292
|
|
|
2019-12-19 |
2019-12-18 |
PS
Planned sale
|
Babler Martin
President, CEO
Executive Director
|
2,205
-11.5%
53.69
USD 118,392
|
2,205
-11.5%
|
53.69
|
USD 118,392
|
|
|
2019-12-19 |
2019-12-18 |
PS
Planned sale
|
Babler Martin
President, CEO
Executive Director
|
1,000
-5.0%
52.77
USD 52,775
|
1,000
-5.0%
|
52.77
|
USD 52,775
|
|
|
2019-12-19 |
2019-12-17 |
PS
Planned sale
|
Babler Martin
President, CEO
Executive Director
|
1,014
-1.8%
54.36
USD 55,116
|
1,014
-1.8%
|
54.36
|
USD 55,116
|
|
|
2019-12-19 |
2019-12-17 |
PS
Planned sale
|
Babler Martin
President, CEO
Executive Director
|
6,661
-10.8%
53.94
USD 359,314
|
6,661
-10.8%
|
53.94
|
USD 359,314
|
|
|
2019-12-19 |
2019-12-17 |
PS
Planned sale
|
Babler Martin
President, CEO
Executive Director
|
11,485
-15.7%
52.86
USD 607,064
|
11,485
-15.7%
|
52.86
|
USD 607,064
|
|
|
2019-12-19 |
2019-12-17 |
PS
Planned sale
|
Babler Martin
President, CEO
Executive Director
|
5,840
-7.4%
51.80
USD 302,502
|
5,840
-7.4%
|
51.80
|
USD 302,502
|
|
|
2019-12-18 |
2019-12-16 |
PS
Planned sale
|
Wolff Stefani
Chief Development Officer
Officer
|
1,300
-3.5%
49.87
USD 64,825
|
1,300
-3.5%
|
49.87
|
USD 64,825
|
|
|
2019-12-18 |
2019-12-16 |
PS
Planned sale
|
Wolff Stefani
Chief Development Officer
Officer
|
4,205
-10.2%
49.29
USD 207,266
|
4,205
-10.2%
|
49.29
|
USD 207,266
|
|
|
2019-12-13 |
2019-12-13 |
PS
Planned sale
|
Hardiman Roy C.
Chief Business Officer
Officer
|
1,619
-1.3%
49.83
USD 80,682
|
1,619
-1.3%
|
49.83
|
USD 80,682
|
|
|
2019-12-13 |
2019-12-13 |
PS
Planned sale
|
Hardiman Roy C.
Chief Business Officer
Officer
|
3,381
-2.7%
49.20
USD 166,352
|
3,381
-2.7%
|
49.20
|
USD 166,352
|
|
|
2019-11-22 |
2019-11-20 |
B
Purchase
|
Becker Daniel J.
Non-Executive Director
|
55,000
+9.0%
29.94
USD 1,646,700
|
55,000
+9.0%
|
29.94
|
USD 1,646,700
|
|
|
2019-11-08 |
2019-11-07 |
PS
Planned sale
|
Goldstein David
Chief Scientific Officer
Officer
|
10,000
-25.1%
32.39
USD 323,914
|
10,000
-25.1%
|
32.39
|
USD 323,914
|
|
|
2019-10-30 |
2019-10-29 |
B
Purchase
|
Becker Daniel J.
|
9,196
+1.5%
33.98
USD 312,477
|
9,196
+1.5%
|
33.98
|
USD 312,477
|
|
|
2019-10-30 |
2019-10-28 |
B
Purchase
|
Becker Daniel J.
|
68,404
+12.8%
33.41
USD 2,285,549
|
68,404
+12.8%
|
33.41
|
USD 2,285,549
|
|
|
2019-10-22 |
2019-10-18 |
B
Purchase
|
GLAXOSMITHKLINE PLC
|
357,142
+13.6%
28.00
USD 9,999,976
|
357,142
+13.6%
|
28.00
|
USD 9,999,976
|
|
|
2019-10-22 |
2019-10-18 |
B
Purchase
|
Becker Daniel J.
|
535,000
+inf%
28.00
USD 14,980,000
|
535,000
+inf%
|
28.00
|
USD 14,980,000
|
|
|
2019-10-22 |
2019-10-18 |
B
Purchase
|
George Simeon
|
357,142
+13.6%
28.00
USD 9,999,976
|
357,142
+13.6%
|
28.00
|
USD 9,999,976
|
|
|
2019-08-15 |
2019-08-13 |
S
Sale
|
New Leaf Ventures II, L.P.
Large shareholder
|
49,991
-11.4%
35.00
USD 1,749,685
|
49,991
-11.4%
|
35.00
|
USD 1,749,685
|
|
|
2019-08-15 |
2019-08-13 |
S
Sale
|
New Leaf Ventures II, L.P.
Large shareholder
|
250,009
-11.4%
35.00
USD 8,750,315
|
250,009
-11.4%
|
35.00
|
USD 8,750,315
|
|
|
2019-05-22 |
2019-05-21 |
S
Sale
|
ORBIMED ADVISORS LLC
Large shareholder
|
1,000,000
-38.4%
30.25
USD 30,250,000
|
1,000,000
-38.4%
|
30.25
|
USD 30,250,000
|
|
|
2018-09-20 |
2018-09-18 |
B
Purchase
|
GLAXOSMITHKLINE PLC
Large shareholder
|
270,000
+11.5%
17.00
USD 4,590,000
|
270,000
+11.5%
|
17.00
|
USD 4,590,000
|
|
|
2018-09-20 |
2018-09-18 |
B
Purchase
|
Becker Daniel J.
Non-Executive Director
Large shareholder
|
270,000
+161.2%
17.00
USD 4,590,000
|
270,000
+161.2%
|
17.00
|
USD 4,590,000
|
|
|
2018-09-20 |
2018-09-18 |
B
Purchase
|
AKKARAJU SRINIVAS
Non-Executive Director
|
175,000
+83.9%
17.00
USD 2,975,000
|
175,000
+83.9%
|
17.00
|
USD 2,975,000
|
|
|
2018-09-20 |
2018-09-18 |
B
Purchase
|
Sofinnova Venture Partners VIII, L.P.
Large shareholder
|
270,000
+15.3%
17.00
USD 4,590,000
|
270,000
+15.3%
|
17.00
|
USD 4,590,000
|
|
|
2018-09-20 |
2018-09-18 |
B
Purchase
|
ORBIMED ADVISORS LLC
Large shareholder
|
250,000
+10.6%
17.00
USD 4,250,000
|
250,000
+10.6%
|
17.00
|
USD 4,250,000
|
|
|
2018-09-20 |
2018-09-18 |
B
Purchase
|
New Leaf Ventures II, L.P.
Large shareholder
|
270,000
+161.2%
17.00
USD 4,590,000
|
270,000
+161.2%
|
17.00
|
USD 4,590,000
|
|
|
2018-09-20 |
2018-09-18 |
B
Purchase
|
George Simeon
Non-Executive Director
Large shareholder
|
270,000
+11.5%
17.00
USD 4,590,000
|
270,000
+11.5%
|
17.00
|
USD 4,590,000
|
|
